|
Post by myocat on May 31, 2017 21:12:20 GMT -5
This is yuge.
|
|
|
Post by porkini on May 31, 2017 21:16:25 GMT -5
Sorry if I missed something and on phone now, but what might the implications or advantages be logistically for a Brazil to UAE transfer of goods? Better than from the US?
|
|
|
Post by mnkdfann on May 31, 2017 21:25:28 GMT -5
What is especially exciting about this deal is that, unlike MannKind here in the USA, Biomm is known and has been respected by the Brazilian medical community for 40+ years. Because Biomm is so well known and were the #1 insulin manufacturer & distributor in Brazil (#4 globally) Technically, that was Biobrás and not Biomm SA. I'm not sure Biomm SA is so well known or respected. Clearly (see previous posts) Biomm's financials are not great (according to Reuters, Bloomberg, etc.). What I posted earlier about healthcare and drugs in Brazil makes me curious to see what Mannkind and Biomm SA can pull off.
|
|
|
Post by mnkdfann on May 31, 2017 21:31:10 GMT -5
investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=1028526... "As a pioneering biotechnology company in Brazil, we believe that we can leverage our current portfolio of diabetes products to offer another option to the significant and growing numbers of patients with diabetes," said Heraldo Marchezini, Diretor Presidente/CEO of Biomm SA. "We are proud to be the first company to bring inhaled mealtime insulin to the Brazilian market." ir.biomm.com/conteudo_en.asp?idioma=1&conta=44&tipo=57030Chief Executive Officer: Heraldo Carvalho Marchezini has over 20 years of solid experience in the pharmaceutical market in various therapeutic segments. Senior VP of the SANOFI Group’s Latin America Region, holding the Presidency of the Brazilian Operation from February 2011 to July 2013 and is responsible for coordinating all the Group‘s companies in the Region ...
|
|
|
Post by boytroy88 on May 31, 2017 21:36:00 GMT -5
investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=1028526... "As a pioneering biotechnology company in Brazil, we believe that we can leverage our current portfolio of diabetes products to offer another option to the significant and growing numbers of patients with diabetes," said Heraldo Marchezini, Diretor Presidente/CEO of Biomm SA. "We are proud to be the first company to bring inhaled mealtime insulin to the Brazilian market." ir.biomm.com/conteudo_en.asp?idioma=1&conta=44&tipo=57030Chief Executive Officer: Heraldo Carvalho Marchezini has over 20 years of solid experience in the pharmaceutical market in various therapeutic segments. Senior VP of the SANOFI Group’s Latin America Region, holding the Presidency of the Brazilian Operation from February 2011 to July 2013 and is responsible for coordinating all the Group‘s companies in the Region ... Hmmm...SNY tie in....things are getting interesting....
|
|
|
Post by mountain74 on May 31, 2017 21:48:22 GMT -5
You gotta think part of making a deal like this where a company is going to invest a lot of time and money to set up distribution of Afrezza in another country that they were assured Afrezza will be available when it's required . Weather it's 9 months or not there is a plan in place where we will be able to sell Afrezza at the date and time needed. Rest assured big companies don't make deals like this if they think the company they are dealing with will be bankrupt. So. I don't care what any naysayers say Afrezza and MannKind is here to stay and will be a huge success. Congrats to all the hard working people at MNKD. Well done.. The company's financials are listed on their webpage unfortunately they're published in Portuguese. So it's impossible to read a know what size company we are dealing with. But at some point in time they were one of the fourth or fifth largest insulin producers in the world. So the company does have some critical mass. 12, million diabetics waiting for Afrezza. Latest quarters: translate.google.com/translate?hl=en&sl=pt&u=http://bvmf.bmfbovespa.com.br/cias-listadas/empresas-listadas/ResumoEmpresaPrincipal.aspx%3FcodigoCvm%3D19305&prev=search
|
|
|
Post by kc on May 31, 2017 21:48:30 GMT -5
What is especially exciting about this deal is that, unlike MannKind here in the USA, Biomm is known and has been respected by the Brazilian medical community for 40+ years. Because Biomm is so well known and were the #1 insulin manufacturer & distributor in Brazil (#4 globally) once they launch Afrezza, I believe you will see very rapid sales growth. They won't face the obstacles MannKind has had to overcome. Great choice, MannKind! Brazil is universal healthcare. But they lack doctors and hospitals. They have 191 million citizens. They need medicines that provide early intervention treatment. That is something Afrezza offers. Early treatment of diabetes reduce cost and complications for their universal healthcare system. MannKind has plenty capacity at their factory in Danbury so they can sell it cheap especially if I have tremendous adoption rate in Brazil. This deal is not about every positional factories in other countries. It's about selling Afrezza. Doctors in countries like Brazil will adept based on the studies that have been produced especially the studies that were presented at the 2016 ADA convention. I would bet that there will be quicker adaption for under 18 years old.
|
|
|
Post by seanismorris on May 31, 2017 21:59:02 GMT -5
The Pediatric study likely doesn't need to be fully US based. Let's partner with Biomm and get it DONE.
Let's hope that they don't operate at the snail pace that MannKind does...
MannKind has been pissing me of with the Pediatric Trial for what seems like years.
|
|
|
Post by buyitonsale on May 31, 2017 22:30:55 GMT -5
Sem falência
|
|
|
Post by buyitonsale on May 31, 2017 22:41:11 GMT -5
A única insulina inalada
|
|
|
Post by seanismorris on May 31, 2017 22:42:27 GMT -5
I agree. Bankruptcy is off the table for the next year, but dilution is live and well. Dilution is going to put a cap on our stock price recovery, but the question is at what level... I figure there is going to be a lot of resistance getting through the $5 (1$ pre split) level. We need to see if Institutional buying returns, and watch the scripts (as always).
|
|
|
Post by peppy on May 31, 2017 23:30:21 GMT -5
What is especially exciting about this deal is that, unlike MannKind here in the USA, Biomm is known and has been respected by the Brazilian medical community for 40+ years. Because Biomm is so well known and were the #1 insulin manufacturer & distributor in Brazil (#4 globally) once they launch Afrezza, I believe you will see very rapid sales growth. They won't face the obstacles MannKind has had to overcome. Great choice, MannKind! Brazil is universal healthcare. But they lack doctors and hospitals. They have 191 million citizens. They need medicines that provide early intervention treatment. That is something Afrezza offers. Early treatment of diabetes reduce cost and complications for their universal healthcare system. MannKind has plenty capacity at their factory in Danbury so they can sell it cheap especially if I have tremendous adoption rate in Brazil. This deal is not about every positional factories in other countries. It's about selling Afrezza. Doctors in countries like Brazil will adept based on the studies that have been produced especially the studies that were presented at the 2016 ADA convention. I would bet that there will be quicker adaption for under 18 years old. I have never been to Brazil. I have been to Mexico. The Much-Debated Mexican Healthcare System. Mexico's healthcare system includes small private systems as well as universal health insurance programs. ... Mexico began its efforts to provide full healthcare coverage in 2004, with a program called Seguro Popular (Popular Health Insurance).
In Mexico, the people with money have private physicians; for instance a large Oceanside housing development in Mexico, where the rich live, has a physician on staff.
Here is my take, correct, or incorrect. If you live in Brazil, your parents better be very wealthy (which there are plenty of wealthy in south America) to get Afrezza.
www.century21global.com/property/79-acapulco-guerrero-39867-mexico-C21110176999-USD www.century21global.com/property/acapulco-guerrero-39390-mexico-C21109458130-USD
|
|
|
Post by mnkdfann on May 31, 2017 23:44:09 GMT -5
|
|
|
Post by peppy on Jun 1, 2017 0:02:18 GMT -5
I opened the 225 page annual report, I saw the same.
|
|
|
Post by goyocafe on Jun 1, 2017 0:02:47 GMT -5
I wouldn't be opposed if every public company in which I was invested came to its current shareholders with an offering before going back to the street. Going to the street doesn't always mean a company is in financial trouble. Consider why a company goes public in the first place. Would you object if it was to fund a capital investment in a packaging plant for Afrezza? I haven't looked at the financial data, so I could be all wet.
|
|